ADMdx has been awarded a Small Business Innovation Research grant from the National Institutes of Aging, focused on the prediction of tau burden in the brain using MRI scans and machine learning. PET tracers for tau have made it possible to measure abnormal tau accumulation, one of the hallmark pathologies of Alzheimer’s disease. Using tau PET scans and structural MRI scans from the same patients, ADMdx will explore the ability to use structural MRI, a broadly available imaging technology, to predict the presence and distribution of abnormal tau.
The results of our collaborative work led by Dr. Lisa Mosconi at Weill Cornell Medical School have been published in the April issue of the journal Neurology. Findings showed that lower adherence to a Mediterranean diet was associated with progressive abnormalities in glucose metabolism (measured using FDG PET imaging) and in amyloid (measured using amyloid PET imaging). These data support further investigation of dietary interventions for protection against brain aging and AD.
Our collaborative work led by Dr. Lisa Mosconi of Weill Cornell Medical College has been published in the March issue of the British Medical Journal, titled “Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer’s disease: a cross-sectional study of middle-aged adults from the broader New York City area”. In this study, brain image analysis showed that a Mediterranean diet and insulin sensitivity explained reductions in the thickness of gray matter in key brain regions for Alzheimer’s disease. This work has important implications for the role of life style factors, particularly diet, in Alzheimer’s disease risk.
ADMdx presents the results of our collaborative work with Siemens Healthcare in quantifying the effects of PET image reconstruction on measured amyloid burden.
ADMdx presented its work in applications of machine learning to critical drug development questions at the American College of Neuropsychopharmacology (ACNP) Conference held in Palm Springs, CA, on December 5, 2017. Examples presented included differentiation of dementias, prediction of cognitive decline, and dose-response of two neuropsychiatric therapeutics.
Results of our application of machine learning to the DIAN early-onset Alzheimer’s disease data set were presented at the Clinical Trials in Alzheimer’s Disease on November 2, 2017, in Boston, MA.
ADMdx to present findings in tau imaging at the 2017 Alzheimer’s Association International Conference (AAIC). This work identifies relationships between the emergence of AD-related hypometabolism, amyloid status, and tau burden across the spectrum of preclinical, prodromal, and dementia stage Alzheimer’s disease.
Dawn Matthews to speak at Traumatic Brain Injury (TBI) symposium, where she will describe Opportunities and Challenges in imaging of TBI. The symposium is focused on the need for initiatives in the diagnosis and treatment of the brain trauma occurring in athletes, military, and other personnel.
ADMdx to present impact of amyloid PET scan alignment on amyloid measurement at the Human Amyloid Imaging (HAI) Meeting. This work, conducted in collaboration with Siemens Healthineers and sponsored through a grant from the Radiologic Society of North America (RSNA), is the first to quantify the error introduced into amyloid measurement due to subject motion.
ADMdx selected as one of 12 Innovator Companies for 2016 by PM360, a journal specializing in the pharmaceutical industry. This award highlights ADMdx’s novel advances in the detection and differentiation of dementias, and in the evaluation of treatment effects upon disease progression.